US FDA approves Amneal's migraine treatment
15/05/2025 13:09
May 15 (Reuters) - Amneal Pharmaceuticals AMRX.O said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study